JP2016500673A5 - - Google Patents

Download PDF

Info

Publication number
JP2016500673A5
JP2016500673A5 JP2015535895A JP2015535895A JP2016500673A5 JP 2016500673 A5 JP2016500673 A5 JP 2016500673A5 JP 2015535895 A JP2015535895 A JP 2015535895A JP 2015535895 A JP2015535895 A JP 2015535895A JP 2016500673 A5 JP2016500673 A5 JP 2016500673A5
Authority
JP
Japan
Prior art keywords
antibody
seq
variable region
chain variable
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015535895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016500673A (ja
JP6511396B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/063945 external-priority patent/WO2014058924A2/en
Publication of JP2016500673A publication Critical patent/JP2016500673A/ja
Publication of JP2016500673A5 publication Critical patent/JP2016500673A5/ja
Application granted granted Critical
Publication of JP6511396B2 publication Critical patent/JP6511396B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015535895A 2012-10-08 2013-10-08 アルファ−シヌクレイン認識抗体 Expired - Fee Related JP6511396B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261711204P 2012-10-08 2012-10-08
US61/711,204 2012-10-08
US201261719281P 2012-10-26 2012-10-26
US61/719,281 2012-10-26
US201361840432P 2013-06-27 2013-06-27
US61/840,432 2013-06-27
US201361872366P 2013-08-30 2013-08-30
US61/872,366 2013-08-30
PCT/US2013/063945 WO2014058924A2 (en) 2012-10-08 2013-10-08 Antibodies recognizing alpha-synuclein

Publications (3)

Publication Number Publication Date
JP2016500673A JP2016500673A (ja) 2016-01-14
JP2016500673A5 true JP2016500673A5 (enExample) 2016-12-01
JP6511396B2 JP6511396B2 (ja) 2019-05-15

Family

ID=50478052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015535895A Expired - Fee Related JP6511396B2 (ja) 2012-10-08 2013-10-08 アルファ−シヌクレイン認識抗体

Country Status (20)

Country Link
US (6) US9605056B2 (enExample)
EP (2) EP3498296A1 (enExample)
JP (1) JP6511396B2 (enExample)
KR (1) KR102163001B1 (enExample)
CN (2) CN104822389B (enExample)
AU (2) AU2013329381B2 (enExample)
BR (1) BR112015007882A2 (enExample)
CA (1) CA2886254A1 (enExample)
EA (1) EA034312B1 (enExample)
ES (1) ES2701406T3 (enExample)
IL (1) IL238192B (enExample)
MX (1) MX365099B (enExample)
MY (1) MY169086A (enExample)
NZ (1) NZ706337A (enExample)
PH (1) PH12015500767B1 (enExample)
SA (1) SA515360253B1 (enExample)
SG (1) SG11201502662QA (enExample)
UA (1) UA118441C2 (enExample)
WO (1) WO2014058924A2 (enExample)
ZA (1) ZA201502213B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
LT3067066T (lt) 2007-02-23 2019-06-25 Prothena Biosciences Limited Sinukleopatinių ir amiloidogeninių ligų prevencija ir gydymas
HRP20230065T1 (hr) 2011-10-28 2023-03-03 Prothena Biosciences Limited Humanizirana protutijela koja prepoznaju alfa-sinuklein
SG11201404321YA (en) 2012-01-27 2014-08-28 Neotope Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US10562973B2 (en) * 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US9732148B2 (en) 2014-10-16 2017-08-15 Genentech, Inc. Anti-α-synuclein antibodies and methods of use
TWI711631B (zh) * 2015-01-28 2020-12-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
CN109475616B (zh) 2016-06-02 2022-10-18 麦迪穆有限责任公司 针对α-突触核蛋白的抗体及其用途
MA46836A (fr) 2016-11-15 2019-09-25 H Lundbeck As Agents, utilisations et procédés pour le traitement d'une synucléinopathie
CA3042302A1 (en) * 2016-12-02 2018-06-07 Prothena Biosciences Limited Infrared assay detecting secondary structure profiles of alpha-synuclein
EP3555127B1 (en) * 2016-12-16 2024-12-18 H. Lundbeck A/S Agents, uses and methods
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
MX2019008029A (es) 2017-01-06 2019-12-11 Abl Bio Inc Anticuerpo anti-alfa-sinucleina y su uso.
EA201991720A1 (ru) * 2017-02-17 2020-01-20 Бристол-Маерс Сквибб Компани Антитела к альфа-синуклеину и их применения
JOP20190227A1 (ar) * 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
WO2018204352A1 (en) 2017-05-01 2018-11-08 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
EP3672635A4 (en) 2017-08-23 2021-05-12 The Trustees of The University of Pennsylvania MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHOD OF USING THEREOF
PE20210042A1 (es) 2017-10-06 2021-01-08 Prothena Biosciences Ltd Metodos para detectar transtiretina
CN111315213B (zh) 2017-10-06 2023-09-12 普罗塞纳生物科学有限公司 抗甲状腺素运载蛋白抗体
AU2018375356A1 (en) 2017-11-29 2020-05-14 Neotope Neuroscience Limited Lyophilized formulation of a monoclonal antibody against transthyretin
CN111886251A (zh) 2017-12-14 2020-11-03 Abl生物公司 抗a-syn/igf1r的双特异性抗体及其用途
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
US11512125B2 (en) 2018-06-27 2022-11-29 Mor Research Applications Antibodies for the treatment of synucleinopathies and neuroinflammation
WO2020079113A1 (en) * 2018-10-19 2020-04-23 Janssen Vaccines & Prevention B.V. Anti-synuclein antibodies
TWI734279B (zh) 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
CN110172098B (zh) * 2019-05-27 2023-03-10 长春工业大学 抗α-突触核蛋白的单克隆抗体及其应用
WO2021000251A1 (en) * 2019-07-02 2021-01-07 Shanghaitech University Antibody to leptin receptor
WO2021055881A1 (en) * 2019-09-20 2021-03-25 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof
EP4400515A3 (en) 2020-04-24 2024-10-23 F. Hoffmann-La Roche AG Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
JP2023526500A (ja) 2020-05-19 2023-06-21 オター プロシーナ リミテッド アルツハイマー病の処置のためのマルチエピトープワクチン
TWI745993B (zh) 2020-06-04 2021-11-11 國立高雄大學 α-突觸核蛋白感測薄膜及其製造方法與用途
WO2022060236A1 (en) * 2020-09-17 2022-03-24 Qatar Foundation For Education, Science And Community Development ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES
WO2022060488A1 (en) * 2020-09-18 2022-03-24 Othair Prothena Limited Multiepitope vaccine for the treatment of alzheimer's disease
US12248291B2 (en) 2021-06-09 2025-03-11 Tyco Fire & Security Gmbh Central energy system with expert subplant models
US12105487B2 (en) 2021-12-06 2024-10-01 Tyco Fire & Security Gmbh Control system for building equipment with optimization search reduction based on equipment models and parameters
CN113912714B (zh) * 2021-12-15 2022-02-22 北京凯祥弘康生物科技有限公司 特异性结合α-突触核蛋白的抗体及其应用
US12292723B2 (en) 2022-01-21 2025-05-06 Tyco Fire & Security Gmbh Generating set of curtailment actions predicted to achieve net consumption target for a subperiod
US12099350B2 (en) 2022-03-04 2024-09-24 Tyco Fire & Security Gmbh Central plant with automatic subplant models
CN115032400A (zh) * 2022-03-28 2022-09-09 首都医科大学附属北京天坛医院 α-突触核蛋白在辅助诊断神经退行性疾病中的用途
US12572135B2 (en) 2022-04-29 2026-03-10 Tyco Fire & Security Gmbh Building equipment control system with dynamic flow bounds
US12282306B2 (en) 2022-04-29 2025-04-22 Tyco Fire & Security Gmbh Control system for building equipment with dynamic capacity constraints
WO2024141576A1 (en) 2022-12-29 2024-07-04 Astrazeneca Ab Compositions and methods for treating alpha-synucleinopathies
KR20240176098A (ko) * 2023-06-14 2024-12-24 경상국립대학교산학협력단 알파 시누클레인 에피토프를 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 조성물

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
JP2000510813A (ja) 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Il−12用処方
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ATE312349T1 (de) * 1998-07-03 2005-12-15 Innogenetics Nv Differentielle diagnose von neurodegeneration
DE60045319D1 (de) 1999-02-05 2011-01-13 Samsung Electronics Co Ltd Verfahren und Vorrichtung zum Wiederauffinden von Texturbildern
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP1531864A4 (en) 2002-05-13 2006-08-23 Alexion Pharma Inc HUMANIZED ANTIBODIES TO THE VENEZOLAN HORSEMEN ENZEPHALITIS VIRUS
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
ES2293096T3 (es) 2002-11-29 2008-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PL1820022T3 (pl) 2004-11-10 2009-11-30 Boehringer Ingelheim Pharma Zastosowanie analizy metodą cytometrii przepływowej w optymalizacji strategii dla banków komórek jajnika chińskiego chomika
CA2657953A1 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
WO2007021255A1 (en) * 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
SG178804A1 (en) 2007-02-23 2012-03-29 Schering Corp Engineered anti-il-23p19 antibodies
PL2118300T3 (pl) 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP5467415B2 (ja) 2007-03-02 2014-04-09 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト タンパク質製造の改良
SI2132230T1 (sl) 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
MX2009010179A (es) 2007-03-22 2010-03-15 Imclone Llc Formulaciones estables de anticuerpo.
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
ES2511844T3 (es) 2007-12-21 2014-10-23 F. Hoffmann-La Roche Ag Formulación de anticuerpo
PT2237803E (pt) 2007-12-28 2015-10-16 Prothena Biosciences Ltd Tratamento e profilaxia da amiloidose
BRPI0906544A2 (pt) 2008-04-05 2019-01-02 Single Cell Tech Inc método de obtenção de informação a partir de células isoladas de interesse.
DK2282758T3 (en) 2008-04-29 2019-02-25 Bioarctic Ab ANTIBODIES AND VACCINES FOR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR ALPHA-SYNUCLEIN-RELATED DISORDERS
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US20120276019A1 (en) 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
DE102008048129A1 (de) 2008-09-20 2010-04-22 Lfk-Lenkflugkörpersysteme Gmbh Flugkörper mit zumindest einem Bremsfallschirm sowie Befestigungsvorrichtung zur Befestigung eines Bremsfallschirms an einem Flugkörper
AU2009298501A1 (en) 2008-09-30 2010-04-08 Abbvie Inc. Improved antibody libraries
EP2364368B1 (en) 2008-11-07 2014-01-15 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
NZ623910A (en) 2009-07-28 2016-06-24 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
EP2470653A1 (en) 2009-08-26 2012-07-04 Research Development Foundation Methods for creating antibody libraries
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2519537A4 (en) 2009-12-29 2013-07-10 Reddys Lab Ltd Dr CLEANING PROTEINS
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US9028830B2 (en) 2010-04-08 2015-05-12 JN Biosciences, LLC Antibodies to CD122
SG185428A1 (en) 2010-06-08 2012-12-28 Genentech Inc Cysteine engineered antibodies and conjugates
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗tim-3抗体
MX343376B (es) 2010-07-15 2016-11-03 Adheron Therapeutics Inc Anticuerpos humanizados que tienen como objetivo el dominio ec1 de cadherina-11 y composiciones y metodos relacionados.
SG10201508401TA (en) 2010-10-11 2015-11-27 Abbvie Bahamas Ltd Processes for purification of proteins
EP2673635A4 (en) 2011-02-07 2015-08-12 Neotope Biosciences Ltd IMMUNOTHERAPY THROUGH APOE
WO2012160536A1 (en) 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
US9845327B2 (en) 2011-06-22 2017-12-19 The General Hospital Corporation Treatment of proteinopathies
WO2013003680A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
HRP20230065T1 (hr) 2011-10-28 2023-03-03 Prothena Biosciences Limited Humanizirana protutijela koja prepoznaju alfa-sinuklein
AR088579A1 (es) 2011-10-31 2014-06-18 Genentech Inc Formulaciones de anticuerpos
SG11201404321YA (en) 2012-01-27 2014-08-28 Neotope Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
RU2711552C2 (ru) 2012-08-29 2020-01-17 Ф. Хоффманн-Ля Рош Аг Шаттл для гематоэнцефалического барьера
US8925815B2 (en) 2012-09-05 2015-01-06 Symbol Technologies, Inc. Checkout system for and method of preventing a customer-operated accessory reader facing a bagging area from imaging targets on products passed through a clerk-operated workstation to the bagging area
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US10084674B2 (en) 2015-09-09 2018-09-25 International Business Machines Corporation Virtual desktop operation and data continuity preservation

Similar Documents

Publication Publication Date Title
JP2016512551A5 (enExample)
JP2016063812A5 (enExample)
JP2020500538A5 (enExample)
HRP20190008T4 (hr) Prevencija i liječenje sinukleinopatske i amiloidogene bolesti
JP2019521649A5 (enExample)
CO2018004532A2 (es) Anticuerpos anti-cd19 humano con alta afinidad
JP2017518258A5 (enExample)
JP2013198490A5 (enExample)
JP2015522252A5 (enExample)
RU2017125758A (ru) Антитела к с5 и способы их применения
RU2016110891A (ru) Антитела к fcrh5, их иммуноконъюгаты и способы их применения
JP2013520996A5 (enExample)
JP2014240385A5 (enExample)
JP2017052784A5 (enExample)
JP2010526028A5 (enExample)
JP2018506277A5 (enExample)
JP2019525728A5 (enExample)
JP2016513682A5 (enExample)
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
HRP20191608T1 (hr) Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida
JP2014205674A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2017536102A5 (enExample)
HRP20221471T1 (hr) Protutijela anti-fgfr3 i postupci za njihovu uporabu
RU2014134747A (ru) Гуманизированные антитела, которые распознают альфа-синуклеин